• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于心脏代谢的慢性疾病:填补知识和临床实践差距:JACC 现状评论。

Cardiometabolic-Based Chronic Disease, Addressing Knowledge and Clinical Practice Gaps: JACC State-of-the-Art Review.

机构信息

Zena and Michael A. Wiener Cardiovascular Institute/Marie-Josée and Henry R. Kravis Center for Cardiovascular Health, Icahn School of Medicine at Mount Sinai, New York, New York.

Peter Munk Cardiac Centre and the Heart and Stroke Richard Lewar Centre, University of Toronto, Toronto, Ontario, Canada.

出版信息

J Am Coll Cardiol. 2020 Feb 11;75(5):539-555. doi: 10.1016/j.jacc.2019.11.046.

DOI:10.1016/j.jacc.2019.11.046
PMID:32029137
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8168371/
Abstract

In the second part of this JACC State-of-the-Art Review, an early and sustainable preventive care plan is described for cardiometabolic-based chronic disease. This plan can improve cardiometabolic health by targeting early mechanistic events to decrease the risk for certain cardiovascular diseases (e.g., coronary heart disease, heart failure, and atrial fibrillation). Included are various prevention modalities, intensive lifestyle interventions, pharmacotherapy and cardiovascular outcome trial evidence, and bariatric/metabolic procedures. A tactical approach of implementing published clinical practice guidelines/algorithms for early behavioral, adiposity, and dysglycemia targeting is emphasized, as well as relevant educational and research implications.

摘要

在这篇 JACC 最新综述的第二部分,描述了一种基于心血管代谢的慢性疾病的早期和可持续的预防保健计划。该计划可以通过针对早期的机制事件来降低某些心血管疾病(如冠心病、心力衰竭和心房颤动)的风险,从而改善心血管代谢健康。其中包括各种预防方法、强化生活方式干预、药物治疗和心血管结局试验证据,以及减肥/代谢手术。强调了实施针对早期行为、肥胖和血糖异常的已发表临床实践指南/算法的策略方法,以及相关的教育和研究意义。

相似文献

1
Cardiometabolic-Based Chronic Disease, Addressing Knowledge and Clinical Practice Gaps: JACC State-of-the-Art Review.基于心脏代谢的慢性疾病:填补知识和临床实践差距:JACC 现状评论。
J Am Coll Cardiol. 2020 Feb 11;75(5):539-555. doi: 10.1016/j.jacc.2019.11.046.
2
Cardiometabolic-Based Chronic Disease, Adiposity and Dysglycemia Drivers: JACC State-of-the-Art Review.基于心脏代谢的慢性疾病、肥胖和糖代谢异常的驱动因素:JACC 最新综述。
J Am Coll Cardiol. 2020 Feb 11;75(5):525-538. doi: 10.1016/j.jacc.2019.11.044.
3
Dysglycemia and Abnormal Adiposity Drivers of Cardiometabolic-Based Chronic Disease in the Czech Population: Biological, Behavioral, and Cultural/Social Determinants of Health.捷克人群中心血管代谢性慢性病的糖代谢异常和异常脂肪驱动因素:健康的生物学、行为学和文化/社会决定因素。
Nutrients. 2021 Jul 8;13(7):2338. doi: 10.3390/nu13072338.
4
Coronavirus and Cardiometabolic Syndrome: JACC Focus Seminar.冠状病毒和心脏代谢综合征:美国心脏病学会焦点研讨会。
J Am Coll Cardiol. 2020 Oct 27;76(17):2024-2035. doi: 10.1016/j.jacc.2020.07.069.
5
Cardiometabolic risk: New chronic care models.心脏代谢风险:新的慢性病护理模式。
JPEN J Parenter Enteral Nutr. 2021 Nov;45(S2):85-92. doi: 10.1002/jpen.2264.
6
Cardiometabolic-based chronic disease: adiposity and dysglycemia drivers of heart failure.基于心脏代谢的慢性疾病:肥胖和血糖异常是心力衰竭的驱动因素。
Heart Fail Rev. 2023 Jan;28(1):47-61. doi: 10.1007/s10741-022-10233-x. Epub 2022 Apr 4.
7
Metabolic phenotyping in people living with obesity: Implications for dietary prevention.肥胖人群的代谢表型:饮食预防的意义。
Rev Endocr Metab Disord. 2023 Oct;24(5):825-838. doi: 10.1007/s11154-023-09830-4. Epub 2023 Aug 15.
8
What is the role of lifestyle behaviour change associated with non-communicable disease risk in managing musculoskeletal health conditions with special reference to chronic pain?与非传染性疾病风险相关的生活方式行为改变在管理肌肉骨骼健康状况(特别是慢性疼痛)中起什么作用?
BMC Musculoskelet Disord. 2015 Apr 13;16:87. doi: 10.1186/s12891-015-0545-y.
9
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.美国临床内分泌医师协会和美国内分泌学会肥胖患者医疗护理综合临床实践指南
Endocr Pract. 2016 Jul;22 Suppl 3:1-203. doi: 10.4158/EP161365.GL. Epub 2016 May 24.
10
Preventing Diabetes and Atherosclerosis in the Cardiometabolic Syndrome.预防心脏代谢综合征中的糖尿病和动脉粥样硬化。
Curr Atheroscler Rep. 2021 Mar 9;23(4):16. doi: 10.1007/s11883-021-00913-8.

引用本文的文献

1
Global, regional and national burden of stroke and subtypes burden in women of reproductive age: insights based on Global Burden of Disease 2021.全球、区域和国家育龄妇女中风及其亚型的负担:基于《2021年全球疾病负担》的见解
BMC Public Health. 2025 Aug 21;25(1):2872. doi: 10.1186/s12889-025-23869-9.
2
The Association Between the Hemoglobin Glycation Index and Cardiometabolic Diseases: A Mini-Review.血红蛋白糖化指数与心脏代谢疾病之间的关联:一篇综述短文
J Clin Hypertens (Greenwich). 2025 Jul;27(7):e70092. doi: 10.1111/jch.70092.
3
Association of single and multiple cardiometabolic diseases with atrial fibrillation: a prospective cohort study.单一及多种心脏代谢疾病与心房颤动的关联:一项前瞻性队列研究。
Open Heart. 2025 Feb 23;12(1):e003034. doi: 10.1136/openhrt-2024-003034.
4
Targeting the Gut-Heart Axis Improves Cardiac Remodeling in a Clinical Scale Model of Cardiometabolic Syndrome.靶向肠-心轴可改善心脏代谢综合征临床规模模型中的心脏重塑。
JACC Basic Transl Sci. 2024 Nov 20;10(1):1-15. doi: 10.1016/j.jacbts.2024.09.004. eCollection 2025 Jan.
5
Association of impaired fasting glucose with cardiometabolic multimorbidity: The Kailuan study.空腹血糖受损与心血管代谢多种疾病的关联:开滦研究
J Diabetes Investig. 2025 Jan;16(1):129-136. doi: 10.1111/jdi.14316. Epub 2024 Oct 24.
6
Primary and residual cardiometabolic risk factors among young adults in a Russian city.俄罗斯城市青年成年人的主要和残余心血管代谢危险因素。
J Health Popul Nutr. 2024 Oct 23;43(1):166. doi: 10.1186/s41043-024-00658-5.
7
Digital Twin in Managing Hypertension Among People With Type 2 Diabetes: 1-Year Randomized Controlled Trial.数字孪生技术在2型糖尿病患者高血压管理中的应用:一项为期1年的随机对照试验。
JACC Adv. 2024 Aug 14;3(9):101172. doi: 10.1016/j.jacadv.2024.101172. eCollection 2024 Sep.
8
Higher neighborhood disadvantage is associated with weaker interactions among cardiometabolic drivers.较高的邻里劣势与心脏代谢驱动因素之间较弱的相互作用有关。
Int J Cardiol Cardiovasc Risk Prev. 2024 Aug 19;23:200322. doi: 10.1016/j.ijcrp.2024.200322. eCollection 2024 Dec.
9
The conceptualisation of cardiometabolic disease policy model in the UK.英国心脏代谢疾病政策模型的概念化。
BMC Health Serv Res. 2024 Sep 13;24(1):1060. doi: 10.1186/s12913-024-11559-y.
10
Serum Dynamin-Related Protein 1 Concentrations Discriminate Phenotypes and Predict Prognosis of Heart Failure.血清动力相关蛋白1浓度可区分心力衰竭的表型并预测其预后。
Rev Cardiovasc Med. 2023 Apr 23;24(4):123. doi: 10.31083/j.rcm2404123. eCollection 2023 Apr.

本文引用的文献

1
CLINICAL PRACTICE GUIDELINES FOR THE PERIOPERATIVE NUTRITION, METABOLIC, AND NONSURGICAL SUPPORT OF PATIENTS UNDERGOING BARIATRIC PROCEDURES - 2019 UPDATE: COSPONSORED BY AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY, THE OBESITY SOCIETY, AMERICAN SOCIETY FOR METABOLIC & BARIATRIC SURGERY, OBESITY MEDICINE ASSOCIATION, AND AMERICAN SOCIETY OF ANESTHESIOLOGISTS - .肥胖患者减重手术围手术期营养、代谢和非手术支持临床实践指南-2019 年更新:美国临床内分泌医师协会/美国内分泌学会、肥胖协会、美国代谢与减重外科学会、肥胖医学协会和美国麻醉师协会共同赞助
Endocr Pract. 2019 Dec;25(12):1346-1359. doi: 10.4158/GL-2019-0406. Epub 2019 Nov 4.
2
Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial.利格列汀与格列美脲对2型糖尿病患者主要不良心血管结局的影响:卡罗来纳州随机临床试验
JAMA. 2019 Sep 24;322(12):1155-1166. doi: 10.1001/jama.2019.13772.
3
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.达格列净治疗射血分数降低的心力衰竭患者。
N Engl J Med. 2019 Nov 21;381(21):1995-2008. doi: 10.1056/NEJMoa1911303. Epub 2019 Sep 19.
4
Primary Prevention of ASCVD and T2DM in Patients at Metabolic Risk: An Endocrine Society* Clinical Practice Guideline.代谢风险患者动脉粥样硬化性心血管疾病和2型糖尿病的一级预防:美国内分泌学会临床实践指南
J Clin Endocrinol Metab. 2019 Sep 1;104(9):3939-3985. doi: 10.1210/jc.2019-01338.
5
Extreme Atherosclerotic Cardiovascular Disease (ASCVD) Risk Recognition.极高危动脉粥样硬化性心血管疾病(ASCVD)风险识别。
Curr Diab Rep. 2019 Jul 22;19(8):61. doi: 10.1007/s11892-019-1178-6.
6
Diabetes as a risk factor for heart failure in women and men: a systematic review and meta-analysis of 47 cohorts including 12 million individuals.糖尿病是女性和男性心力衰竭的危险因素:包括 1200 万人在内的 47 项队列的系统评价和荟萃分析。
Diabetologia. 2019 Sep;62(9):1550-1560. doi: 10.1007/s00125-019-4926-x. Epub 2019 Jul 18.
7
Association between pre-ablation bariatric surgery and atrial fibrillation recurrence in morbidly obese patients undergoing atrial fibrillation ablation.肥胖患者行房颤消融术前减重手术与房颤复发的相关性。
Europace. 2019 Oct 1;21(10):1476-1483. doi: 10.1093/europace/euz183.
8
Risk for Heart Failure: The Opportunity for Prevention With the American Heart Association's Life's Simple 7.心力衰竭风险:美国心脏协会“生命的七大简单要素”预防的机会。
JACC Heart Fail. 2019 Aug;7(8):637-647. doi: 10.1016/j.jchf.2019.03.009. Epub 2019 Jul 10.
9
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.度拉糖肽与 2 型糖尿病患者的心血管结局(REWIND):一项双盲、随机、安慰剂对照试验。
Lancet. 2019 Jul 13;394(10193):121-130. doi: 10.1016/S0140-6736(19)31149-3. Epub 2019 Jun 9.
10
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.口服司美格鲁肽与 2 型糖尿病患者的心血管结局。
N Engl J Med. 2019 Aug 29;381(9):841-851. doi: 10.1056/NEJMoa1901118. Epub 2019 Jun 11.